Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from CervoMed ( (CRVO) ) is now available.
CervoMed reported first-quarter 2026 results on May 18, 2026, highlighting continued progress with its lead candidate neflamapimod across multiple neurodegenerative indications. The company completed Phase 3 trial design for dementia with Lewy bodies in consultation with U.S. and global regulators, selected a new stable crystal formulation and dosing regimen, and presented placebo-controlled MRI data and biomarker analyses suggesting reversible basal forebrain disease progression and greater benefit in patients with lower pTau181 levels, reinforcing neflamapimod’s DLB-specific mechanism.
Beyond DLB, CervoMed advanced a Phase 2a trial in non-fluent variant primary progressive aphasia, with U.S. enrollment completed and U.K. enrollment under way, and secured inclusion of neflamapimod in the U.K.’s EXPERTS-ALS platform trial in February 2026 to test the drug in amyotrophic lateral sclerosis. The company also obtained a European patent in March 2026 covering p38 alpha MAP kinase inhibitors for DLB treatment, while disclosing a cash balance of $12.9 million as of March 31, 2026, down from $20.9 million at year-end and expected to fund operations into the third quarter of 2026, underscoring a growing funding need as it targets multiple mid- to late-stage milestones this year.
Financially, CervoMed’s first-quarter 2026 results showed no grant revenue compared with $1.9 million a year earlier following completion of the RewinD-LB trial and the exhaustion of associated National Institute on Aging grant funding. Research and development expenses rose to $5.1 million and general and administrative costs to $3.0 million, driving a wider net loss of $8.0 million versus $4.9 million in the prior-year period, as the company invested in new manufacturing processes, ongoing clinical programs, and corporate infrastructure.
The most recent analyst rating on (CRVO) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.
Spark’s Take on CRVO Stock
According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large losses, and significant cash burn) and bearish technicals (price below key moving averages with negative MACD). Offsetting these, recent corporate events around neflamapimod show positive clinical/biomarker progress and Phase 3 planning momentum, but valuation support is limited due to a negative P/E and no dividend yield data.
To see Spark’s full report on CRVO stock, click here.
More about CervoMed
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders. Its lead investigational drug, neflamapimod, is an orally administered small molecule targeting p38 alpha MAP kinase to address neuroinflammation and synaptic dysfunction in conditions such as dementia with Lewy bodies, recovery after ischemic stroke, and primary progressive aphasia. The company is positioning itself in neurodegenerative disease markets where disease-modifying therapies remain limited, aiming to leverage biomarker-driven patient selection and regulatory alignment to advance late-stage trials.
Average Trading Volume: 66,323
Technical Sentiment Signal: Sell
Current Market Cap: $31.85M
See more insights into CRVO stock on TipRanks’ Stock Analysis page.